<DOC>
	<DOCNO>NCT02247310</DOCNO>
	<brief_summary>Considering significance early consequent Multiple Sclerosis ( MS ) treatment well challenge achieve high adherence treatment , evaluate benefit new measure improve adherence important . The data storage capability BETACONNECT device , include automate recording injection , facilitate collection reliable data patient 's injection behavior adherence , unaffected recall bias report bias . To good understand utility new BETACONNECT device characterize contribution adherence , plan prospectively follow-up MS patient use device 24 week . The study take place real-life set Neurology center across Europe .</brief_summary>
	<brief_title>BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence EVALuation Multiple Sclerosis Patients Treated With Betaferon</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Patients diagnosis relapse remit multiple sclerosis clinically isolated syndrome . Patients must treatment Betaferon decision treat patient Betaferon make attend physician . Patient attend physician must agree usage BETACONNECT autoinjector device . Written informed consent must obtain . Patients receive disease modify drug . Contraindications Betaferon describe Summary Product Characteristics .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>